Ogeda Seeks Financing After Successful Phase II For Non-Hormonal Menopause Drug

Ogeda's non-hormonal menopause therapy, fezolinetant, has produced positive results in Phase II – an important step for the small Belgian biotech as it looks for partners or investment from further afield.